Hyperinsulinemic Hypoglycemia Cell Models for Research

Hyperinsulinemic hypoglycemia (HH) is a rare but serious condition characterized by inappropriately high insulin secretion leading to severe hypoglycemia. The incidence is estimated at 1 in 50,000 live births for the congenital forms (WHO). In adults, insulinomas have an incidence of 1-4 per million per year (NCI). The clinical impact is significant: recurrent hypoglycemia can cause neuroglycopenic symptoms, seizures, and permanent brain damage, especially in neonates. The mortality rate is low but morbidity is high. Early diagnosis and management are critical. Research focuses on understanding the molecular mechanisms of insulin secretion dysregulation and developing targeted therapies.

HH is an ideal model for studying beta-cell function and insulin secretion pathways. The disease is heterogeneous, with multiple genetic causes (e.g., mutations in ABCC8, KCNJ11, GCK, GLUD1, HADH, UCP2). Public datasets from TCGA and COSMIC provide mutation frequencies and clinical correlations. Open questions include the precise role of each gene in beta-cell physiology, the mechanisms of drug resistance in insulinomas, and the development of novel therapeutic targets. Gene-edited cell models allow precise manipulation of these genes to dissect pathways and test interventions.

In HH, the primary defect is dysregulated insulin secretion from pancreatic beta-cells. Key pathways include:

• • ATP-sensitive potassium (K_ATP) channel pathway: Mutations in ABCC8 (SUR1) and KCNJ11 (Kir6.2) impair channel function, leading to membrane depolarization and continuous insulin release.
• • Glucose-sensing pathway: Activating mutations in GCK (glucokinase) lower the glucose threshold for insulin secretion, causing inappropriate insulin release at low glucose levels.
• • Amino acid metabolism pathway: Mutations in GLUD1 (glutamate dehydrogenase) or HADH (hydroxyacyl-CoA dehydrogenase) affect amino acid-stimulated insulin secretion.
• • Mitochondrial pathway: UCP2 mutations alter mitochondrial function and insulin secretion.

Data from TCGA and COSMIC for insulinomas show somatic mutations in MEN1, YY1, and other genes, but the above are most relevant for HH.

The deregulated networks in HH converge on insulin secretion. Key nodes include:

• • KATP channel complex: SUR1 (ABCC8) and Kir6.2 (KCNJ11) are central. Loss-of-function mutations cause continuous depolarization and insulin release.
• • Glucokinase (GCK): Acts as a glucose sensor. Activating mutations increase glucose affinity, leading to insulin secretion at lower glucose levels.
• • Glutamate dehydrogenase (GLUD1): Activated by ADP, inhibited by GTP. Activating mutations increase sensitivity to amino acids, stimulating insulin secretion.
• • Mitochondrial metabolism: HADH and UCP2 modulate ATP production. Mutations affect the ATP/ADP ratio, influencing KATP channel activity.
• • Calcium signaling: Increased cytosolic calcium triggers insulin granule exocytosis. Mutations that depolarize the membrane increase calcium influx.

Organoids derived from patient iPSCs or pancreatic tissue can recapitulate beta-cell function and are useful for studying HH. They can be gene-edited to introduce or correct mutations.

• • PDX models: Patient-derived xenografts of insulinomas in immunodeficient mice. Useful for drug testing but limited for mechanistic studies.
• • GEMMs (Genetically Engineered Mouse Models): Knock-in mice with activating GCK mutations or knock-out of ABCC8/KCNJ11. These models recapitulate HH phenotypes and are valuable for studying disease mechanisms.
• • Induced models: Chemical induction of insulinomas using streptozotocin or other agents. Less specific but can be used for screening.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise mutations in HH-associated genes. For example:

• • ABCC8 knockout cell lines: Generated in INS-1 or EndoC-βH1 cells to model loss-of-function mutations. These lines exhibit constitutive insulin secretion.
• • KCNJ11 knockout cell lines: Similar to ABCC8 knockouts, they impair K_ATP channel function.
• • GCK knock-in cell lines: Introducing activating mutations (e.g., V455M) into GCK lowers the glucose threshold for insulin secretion.
• • GLUD1 knock-in cell lines: Activating mutations (e.g., S445L) increase sensitivity to amino acids.

These gene-edited models are commercially available from various sources and are sequence-verified. They provide a controlled system to study the functional consequences of specific mutations and to screen for therapeutic compounds. Using isogenic pairs (wild-type vs. mutant) allows for direct comparison and reduces confounding factors.

Gene-edited cell lines are used to validate the role of specific genes in insulin secretion. For example:

• • ABCC8 knockout in INS-1 cells confirms the necessity of K_ATP channels for glucose-stimulated insulin secretion.
• • GCK knock-in with an activating mutation demonstrates the effect on glucose sensitivity.
• • GLUD1 knock-in shows increased amino acid-induced insulin secretion.

These models allow researchers to study gene function in a controlled environment and to identify downstream effectors.

Isogenic cell pairs (wild-type vs. mutant) are powerful for drug screening. For example:

• • Diazoxide is a K_ATP channel opener used to treat HH. Testing on ABCC8 knockout cells can reveal whether the drug's efficacy depends on the channel.
• • Somatostatin analogs (e.g., octreotide) inhibit insulin secretion. Screening on mutant cells can identify resistance mechanisms.
• • mTOR inhibitors (e.g., rapamycin) have been used in some cases. Gene-edited models can help identify responders.

By comparing drug responses between wild-type and mutant cells, researchers can identify compounds that specifically target the mutant pathway.

CRISPR-based synthetic lethality screens can identify genes that are essential in mutant cells but not in wild-type cells. For example:

• • In ABCC8 knockout cells, a genome-wide CRISPR screen could identify genes that, when knocked out, reduce insulin secretion, providing potential therapeutic targets.
• • In GCK knock-in cells, screens can identify genes that reverse the hypersensitivity to glucose.

These screens can also identify biomarkers for diagnosis or prognosis.